Jonathan Webster Profile
Jonathan Webster

@LeukDocWebster

Followers
172
Following
9
Media
1
Statuses
16

Assistant Professor of Oncology, Division of Hematologic Malignancies, Leukemia Group, Johns Hopkins University

Baltimore, MD
Joined November 2021
Don't wanna be here? Send us removal request.
@Hopkins_HemOnc
Johns Hopkins Hematology and Oncology Fellowship
1 year
Congratulations to our fellows (@SaumyaMaruMDPhD, Neha Verma, @mnakazawa7, Nazila Shafagati, Daniel Shu, @michaelconroy, Jesse Handler) on their @ConquerCancerFd #ASCOYIA awards and former fellow and current @hopkinskimmel Asst. Prof. Eric Christenson for the #ASCOCDA!
2
7
38
@KMonty_MD
Kristina Montemayor
2 years
Congratulations @ANiranjanAzadi #OslerPride
@HopkinsHospMed
Hopkins Hospital Medicine
2 years
Congratulations to one of our great Hospitalists @ANiranjanAzadi who was just named Physician of the Year for the @SocietyHospMed MD Chapter!
0
4
22
@GvHD_Meade
Javier Bolaños Meade, MD
2 years
An incredible amount of work with really brilliant people made #BMTCTN1703 a success and the new SOC for #GvHD prophylaxis #PTCyRules #BMTCTN @CIBMTR Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis | NEJM
Tweet card summary image
nejm.org
In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease (GVHD)....
22
93
231
@Hopkins_HemOnc
Johns Hopkins Hematology and Oncology Fellowship
2 years
Congratulations to the graduating class of 2023! We are so proud of you, we love you, and we will miss you. You are all going to do great things!
0
9
58
@LeukDocWebster
Jonathan Webster
2 years
Sending @cappelliMD off to Milan for #EULAR2023 #aleagueoftheirown
0
0
10
@LeukDocWebster
Jonathan Webster
2 years
Great article from @NicholasShortMD and colleagues with important implications for MRD monitoring in Ph+ ALL and our understanding of the fundamental biology underlying Ph+ ALL vs de novo lymphoid blast crisis of CML vs ?Ph+ ALL with CML-like biology.
@NicholasShortMD
Nicholas Short MD
2 years
👉👉Our new paper in @AjHematology on #MRD in Ph+ #ALL. High rates of discordance between NGS for IG/TR and PCR for BCR::ABL1. High sensitivity NGS MRD may be superior to PCR and identifies PCR+ pts with low risk of relapse. Important implications for MRD monitoring in Ph+ ALL.
1
0
6
@PratzKW
Keith W Pratz MD
3 years
#ASH2022 Late breaking abstract on frontline Blinatumomab in adult ALL E1910. Amazing results and new SOC. Congratulations Mark Litzow and study team.
0
5
22
@PratzKW
Keith W Pratz MD
3 years
@DrChrisHourigan⁩ presenting words of wisdom from our great mentor Judy Karp at the #ASH22 AML education session.
0
8
40
@redcell_doc
Rakhi Naik, MD MHS
3 years
Embargo lifted! Congratulations to our @HopkinsHeme trainees who were awarded ASH Abstract Achievement Awards!! 🌟Michael Hochman @mjhochman, Chief Heme Fellow @Hopkins_HemOnc 🌟Macy Early @macy_early, ASH Med Student PS Awardee 🌟 Jayla Scott, Hopkins Woodrow Wilson Awardee 🧵
6
5
52
@HopkinsThoracic
Johns Hopkins Thoracic Oncology
3 years
Congratulations to Dr. @kamarroneMD on receipt of a multi-year career development award from @LUNGevity to study neoadjuvant immunotherapy and targeted therapy for surgical lung cancer harboring a #kras mutation! https://t.co/GBrtqPqI6j
19
10
105
@LeukDocWebster
Jonathan Webster
3 years
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease | Leukemia
Tweet card summary image
nature.com
Leukemia - Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease
0
0
2
@PratzKW
Keith W Pratz MD
3 years
We are happy to share @DrAndyMatthews work on: Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Thx @SelinaLugerMD @ParalkarLab and UPenn leukemia team https://t.co/VpIBgoKDKh
4
30
92
@DrChrisHourigan
Chris Hourigan
3 years
Live action footage of https://t.co/Ao8A96N3Bf arrival at #ASCO2022 Huge AML MRD dataset to present on Tuesday - but also the hoping to use this time away to write the paper...
1
3
24
@KatieLaiMD_MPH
Dr. Catherine Lai
4 years
Working on a podcast to highlight women pioneers in leukemia. Who do you want to hear from? Also, please re-tweet 👍
44
63
176
@LeukDocWebster
Jonathan Webster
4 years
Clonal Hematopoiesis in Donor May Improve Bone Marrow Transplant Outcome. Great work from ⁦@LukaszPGondek
1
1
7
@LeukDocWebster
Jonathan Webster
4 years
Like my decision to join Twitter, this article has been many years in the making. @Dr_BDSmith https://t.co/0a1ND2V2Vr
0
1
10